NULISA Platform Performance Across 10 Plus Alternative Sample Types CSF, Dried Blood Spots, Urine, Saliva, Tear Fluid Detectability Data

  Alamar Biosciences has published comprehensive performance data for the NULISA proteomics platform across more than 10 alternative sample types. The data, authored by Geoffrey Feld, Ph.D. (Geocyte LLC and Alamar Biosciences), demonstrates the following detectability for the NULISAseq Inflammation Panel 250: interstitial fluid (95% plus), synovial fluid (95% plus), CSF (85% plus), dried blood spots (80 95%), saliva (75 85%), nasal swabs (70 80%), tear fluid (60 75%), urine (45 75%). All samples measured at attomolar sensitivity with a 12 log dynamic range without dilution. Full data: https://alamarbio.com/ultra sensitive proteomics alternative sample types/ 

Comments

Popular posts from this blog

Self-Healing Concrete Market 2023 Share, Trend, Segmentation and Forecast to 2028

Geosynthetics Market Size, Share, Growth, Scope, current and Future Growth Forecast by 2030

Goat Milk Market Size, Share, Trends, Key Drivers, Demand And Opportunities